Stockscreener 앱 받기
73.18
20.50%
12.45
시간 외 거래:
73.10
-0.08
-0.11%
전일 마감가:
$60.73
열려 있는:
$68.9
하루 거래량:
9.73M
Relative Volume:
4.15
시가총액:
$7.69B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+39.60%
1개월 성능:
+41.00%
6개월 성능:
+185.30%
1년 성능:
+0.00%
1일 변동 폭
$68.00
$74.24
1주일 범위
$51.92
$74.24
52주 변동 폭
$12.30
$74.24
Metsera Inc Stock (MTSR) Company Profile
명칭
Metsera Inc
전화
(212) 784-6595
주소
3 WORLD TRADE CENTER, NEW YORK
MTSR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
73.18 | 6.39B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | 개시 | Leerink Partners | Outperform |
| 2025-06-20 | 개시 | Wells Fargo | Overweight |
| 2025-02-25 | 개시 | BofA Securities | Buy |
| 2025-02-25 | 개시 | Evercore ISI | Outperform |
| 2025-02-25 | 개시 | Guggenheim | Buy |
모두보기
Metsera Inc 주식(MTSR)의 최신 뉴스
Metsera in the middle of Novo, Pfizer bidding war - BioWorld MedTech
Vital Signs: Pfizer and Novo Nordisk battle for Metsera's pound of flesh - FirstWord Pharma
Pfizer Weight-Loss $9B Suit: Delaware Court Holds Off Amid High-Stakes Fight Over Metsera - USA Herald
Pfizer ‘Unwavering’ In Pursuit Of Metsera - Citeline News & Insights
Pfizer Files Lawsuits Against Metsera and Novo Nordisk | PharmExec - Pharmaceutical Executive
Vice Chancellor Zurn Rejects TRO on Novo Nordisk-Metsera Deal During Active Bidding Process - Law.com
Pfizer Earnings: In-Line Quarter Despite Covid Product Weakness as Metsera Drama Intensifies - Morningstar
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion - Investor's Business Daily
Novo Nordisk Boosts Metsera Bid To $10B After Pfizer Suit - Law360
How Pfizer's (PFE) Metsera Legal Fight and Q3 Dip Could Reshape Its Innovation Strategy - Yahoo Finance
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It - Benzinga
Pfizer and Novo fatten their bids for weight-loss drugmaker Metsera - Axios
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb - Benzinga
Novo Nordisk ups Metsera offer to $10B, outbidding Pfizer - The Business Journals
Novo Nordisk Outbids Pfizer In $10 Billion Metsera Takeover Battle - Finimize
Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera - Barron's
Palantir, Hertz, Metsera, Uber, DraftKings: Stocks Making The Biggest Moves Today - Stocktwits
Teneo Refs Bidding War for Metsera - O'Dwyer's PR
Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle - MarketScreener
Pfizer Metsera Lawsuit - Buffalo News
M&A News: Novo Nordisk Stock (NVO) Slides after Increasing Its Metsera Offer to $10B - TipRanks
Pfizer, Novo Boost Bids for Obesity Drugmaker Metsera in Takeover Saga - Bloomberg
Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera By Reuters - Investing.com
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo - WTAQ
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer - WFMZ.com
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera - Proactive financial news
Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera - Reuters
Metsera’s Shares Spike Amid Acquisition Proposals from Novo Nordisk and Pfizer - StocksToTrade
Takeover Saga for Obesity Drugmaker Metsera Heats Up - Bloomberg
Metsera rises after Novo Nordisk and Pfizer sweeten bids - TradingView
Novo Nordisk (NVO) Raises Bid to Acquire Metsera, Outbidding Pfi - GuruFocus
Delaware court won't rule on Pfizer/Novo battle for Metsera today - Seeking Alpha
Metsera again chooses Novo as bidding war with Pfizer intensifies - BioPharma Dive
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo By Reuters - Investing.com
Metsera Surges as Novo Nordisk Attempts Major Acquisition - timothysykes.com
Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera - BioSpace
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up - Yahoo Finance
Metsera Considers Novo Nordisk’s Superior Acquisition Proposal - TipRanks
Novo Nordisk’s (NVO) $9B Metsera Bid Sparks Showdown with Archrival Pfizer (PFE) - TipRanks
Metsera receives amended ‘superior’ proposal from Novo Nordisk - TipRanks
Metsera saga continues, with upped bids from Novo and Pfizer - The Pharma Letter
Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup - The Wall Street Journal
Pfizer & Novo boost Metsera bids, Hertz stock skyrockets - Yahoo Finance
Metsera Inc Declares Novo Nordisk Proposal Superior - TradingView
Metsera Gets 'Superior' Acquisition Bid From Novo Nordisk, Challenging Pfizer Merger - MarketScreener
Novo Nordisk (NVO) Extends Enhanced Acquisition Offer for Metser - GuruFocus
/C O R R E C T I O N -- Metsera, Inc./ - Placera.se
Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight - Reuters
NVO's Acquisition Offer Values Metsera at $10B - GuruFocus
Metsera to resume trading at 9:50 am ET - TipRanks
Novo, Pfizer's bidding war heats up with supercharged offers for Metsera - Fierce Biotech
Metsera Inc (MTSR) 재무 분석
Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):